Filing Flows › Comparisons › SUPN vs TVTX
Supernus Pharmaceuticals vs Travere Therapeutics: SUPN and TVTX compared
Supernus Pharmaceuticals is the larger company: $227M of revenue in its latest quarter (Q3 2026) against $225M for Travere Therapeutics (Q3 2026). Travere Therapeutics is growing faster (+36% against +18% a year earlier). Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against -30.3%.
Where the money goes: SUPN and TVTX
Supernus Pharmaceuticals (SUPN) · Q3 2026
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Travere Therapeutics (TVTX) · Q3 2026
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
| Supernus Pharmaceuticals (SUPN) | Travere Therapeutics (TVTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $227M | $225M |
| Revenue growth, Y/Y | +18% | +36% |
| Operating margin | 9.3% | -30.3% |
| Net earnings | $20.9M | −$52.3M |
| Net margin | 9.2% | -23.3% |
| Operating cash flow | $6.6M | $98.2M |
| Free cash flow | $6.4M | — |
Where the revenue comes from
Supernus Pharmaceuticals
- Net product sales: $179M (79%)
- ONAPGO: $17.1M (8%)
- Trokendi XR: $10.2M (5%)
- Oxtellar XR: $8.0M (4%)
Travere Therapeutics
- Total net product sales: $220M (98%)
- License and collaboration revenue: $4.4M (2%)
Questions
Which is bigger, Supernus Pharmaceuticals or Travere Therapeutics?
Supernus Pharmaceuticals is the larger company: $227M of revenue in its latest quarter (Q3 2026) against $225M for Travere Therapeutics (Q3 2026).
Is Supernus Pharmaceuticals or Travere Therapeutics growing faster?
Travere Therapeutics is growing faster (+36% against +18% a year earlier).
Which is more profitable, Supernus Pharmaceuticals or Travere Therapeutics?
Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against -30.3%.
More: Supernus Pharmaceuticals earnings · how Supernus Pharmaceuticals makes money · Travere Therapeutics earnings · how Travere Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.